Nicole Lamanna

NewYork–Presbyterian Hospital — United States

Medicine · Health Sciences

38h-index8.5kcitations378works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(293), Lymphoma Diagnosis and Treatment(153), Chronic Myeloid Leukemia Treatments(60), Immunodeficiency and Autoimmune Disorders(56), Advanced Breast Cancer Therapies(52)

Publications378 total

Treatment-Emergent Coagulopathy During Azacitidine/Venetoclax Induction in AML
Blood Neoplasia·2026Open Access
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis
Figshare·2026Open Access
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis
Figshare·2026Open Access
Table S5 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Key Resources Table from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Table S4 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Table S3 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Table S7 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Table S8 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Table S1 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Table S2 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Supplementary Figures S1-S6 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Table S6 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis
Current Medical Research and Opinion·2025
Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience
Blood·2025Open Access
Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Results from the ALPINE trial
Blood·2025
Treatment patterns for del(17P)/mutated <i>TP53</i> or relapsed/refractory (R/R) CLL among experts and lower-volume treaters.
JCO Oncology Practice·2025
Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Oncology and Therapy·2025Open Access
POSTER: CLL-483 Adverse Events of Interest With Zanubrutinib vs Fixed-Duration Combination of Venetoclax + Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia
Clinical Lymphoma Myeloma & Leukemia·2025
CLL-483: Adverse Events of Interest With Zanubrutinib vs Fixed-Duration Combination of Venetoclax + Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 19Next →

Frequent Co-authors

Anthony R. Mato(18), Ian W. Flinn(15), Paul M. Barr(15), Bruce D. Cheson(14), Andrew D. Zelenetz(14), Constantine S. Tam(14), Chaitra S. Ujjani(13), Lindsey E. Roeker(12), Thomas J. Kipps(11), Alan P Skarbnik(11), Toby A. Eyre(11), Steven Coutré(10), Susan O’Brien(10), Stephen J. Schuster(10), Wojciech Jurczak(10), Mazyar Shadman(10), Paolo Ghia(9), Danielle M. Brander(9), Jeffrey J. Pu(9), Nirav N. Shah(9)